The virus that causes cervical cancer is circulating in the cervix and may be causing symptoms similar to the flu, according to a new study.
Researchers from the University of California San Francisco, San Diego and the University at Buffalo in New York tested cervical cells from 1,800 women, looking at whether they had the virus that can cause the symptoms of pregnancy rash and other symptoms associated with the virus.
They found the virus was not present in the cells.
Cervical cells are the body’s natural defense against invading viruses and bacteria.
They contain a layer of immune cells that prevent viruses from reaching the blood.
“We were able to show that HPV-16 does not exist in the cervical mucus, and that it’s not the type of virus that is causing the symptoms in women who are experiencing pregnancy rash,” said Dr. Paul Bock, the study’s senior author.
“The cervical mucous barrier in cervical cancer patients does not protect against HPV-18, so it’s a little bit concerning,” said lead researcher Dr. Robert Krieger.
“We think that the immune cells of the cervical epithelium are the ones that are protecting against HPV, but they’re not actually protecting against other viruses.”
“This is very exciting because we are able to look at the immune system, and we’re able to find the specific cell types that are doing their job,” Kriege added.
The researchers are now working to see if HPV vaccines can be given to women who have contracted the virus and who have experienced some of the symptoms associated to the disease.
If a vaccine is developed that can prevent the virus from entering the body, the researchers are also looking at how vaccines might be given, particularly to people with cervical cancer, in order to see how they affect cervical mucosae.
They plan to continue to investigate whether the virus is present in other tissues, and also to see whether there is a vaccine candidate that would be a better choice than the current vaccine candidate, called Gardasil, which is also being tested in women.
The HPV vaccine is a type of HPV vaccine that can be used in women over the age of 12.
It was approved in late 2016 and is currently available for sale in the United States.